News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
106last 24h
3125last 7d
511● bullish (7d)
311● bearish (7d)
227publishers
Business Wire3d agoneutral
AbCellera to Present at the UBS Global Biopharma Conference on November 17, 2026MT Newswires9d agobullish
Jefferies & Co Initiates Coverage on AbCellera Biologics With Buy Rating, $21 Price TargetBusiness Wire17d agoneutral
AbCellera to Present at Upcoming Investor Conferences in November 2026MT Newswires27d agoneutral
AbCellera Biologics' ABCL635 Seen With Best-in-Class Potential in Menopause, UBS SaysSimply Wall St.30d agoneutral
AbCellera Biologics (ABCL) Could Be 27% Undervalued As ABCL635 Data Draws FocusMT Newswires30d agoneutral
AbCellera to Present Phase 1/2 ABCL635 Data at Menopause Society MeetingBusiness Wire31d agoneutral
AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual MeetingBusiness Wire38d agoneutral
AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026Insider Monkey85d agobullish
AbCellera (ABCL) Soars 64% as Drug Candidate Holds Huge Market OpportunitySimply Wall St.88d agoneutral
AbCellera Biologics (ABCL) Stock Sees Fair Value Lift After Clinical Data And Jazz DealSimply Wall St.89d agoneutral
AbCellera Biologics (ABCL) Could Be 33% Overvalued Following ABCL635 Phase 2 ResultsSimply Wall St.89d agoneutral
AbCellera Biologics (ABCL) Gets Its First Pipeline Win With Positive Phase 2 DataInsider Monkey90d agoneutral
AbCellera (ABCL) Rockets 44% as Hot Flash Treatment Brightens Growth Outlook